Latest Insider Transactions at Myovant Sciences Ltd. (MYOV)
This section provides a real-time view of insider transactions for Myovant Sciences Ltd. (MYOV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Myovant Sciences Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Myovant Sciences Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2023
|
David C Marek Principal Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
417,599
-61.46%
|
-
|
|
Mar 10
2023
|
Uneek Mehra Principal Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
202,696
-55.11%
|
-
|
|
Mar 10
2023
|
Lauren Merendino Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
169,538
-56.43%
|
-
|
|
Mar 10
2023
|
Myrtle S Potter Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Nancy Valente Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
246,684
-67.55%
|
-
|
|
Mar 10
2023
|
Terrie Curran Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Mark Guinan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Adele M. Gulfo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
354,303
-65.97%
|
-
|
|
Mar 10
2023
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
51,599,200
+52.98%
|
$1,393,178,400
$27.0 P/Share
|
|
Mar 03
2023
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,243,005
-8.48%
|
-
|
|
Jan 18
2023
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,008
-1.17%
|
$52,208
$26.89 P/Share
|
|
Jan 18
2023
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
1,272
-0.36%
|
$33,072
$26.89 P/Share
|
|
Jan 18
2023
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,109
-0.45%
|
$28,834
$26.89 P/Share
|
|
Jan 18
2023
|
David C Marek Principal Executive Officer |
SELL
Open market or private sale
|
Direct |
8,037
-1.89%
|
$208,962
$26.89 P/Share
|
|
Jan 04
2023
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
2,779
-0.78%
|
$72,254
$26.9 P/Share
|
|
Jan 04
2023
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,251
-0.9%
|
$58,526
$26.9 P/Share
|
|
Dec 16
2022
|
Uneek Mehra Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
2,241
-1.09%
|
$58,266
$26.75 P/Share
|
|
Oct 26
2022
|
Nancy Valente Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,859
+50.0%
|
-
|
|
Oct 26
2022
|
Myrtle S Potter Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,859
+50.0%
|
-
|
|
Oct 26
2022
|
Adele M. Gulfo Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,859
+50.0%
|
-
|
|
Oct 26
2022
|
Mark Guinan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,859
+50.0%
|
-
|
|
Oct 26
2022
|
Terrie Curran Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,859
+50.0%
|
-
|
|
Oct 18
2022
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,703
-0.98%
|
$42,575
$25.2 P/Share
|
|
Oct 18
2022
|
David C Marek Principal Executive Officer |
SELL
Open market or private sale
|
Direct |
11,156
-2.55%
|
$278,900
$25.2 P/Share
|
|
Oct 18
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
1,933
-0.54%
|
$48,325
$25.2 P/Share
|
|
Oct 18
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,604
-0.64%
|
$40,100
$25.2 P/Share
|
|
Oct 04
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
3,679
-1.01%
|
$88,296
$24.4 P/Share
|
|
Oct 04
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,738
-1.08%
|
$65,712
$24.4 P/Share
|
|
Sep 16
2022
|
Uneek Mehra Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
9,243
-4.32%
|
$166,374
$18.86 P/Share
|
|
Aug 15
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
31,214
-7.9%
|
$561,852
$18.23 P/Share
|
|
Aug 12
2022
|
Matthew Lang General Counsel & Corp. Secy. |
BUY
Grant, award, or other acquisition
|
Direct |
124,780
+24.0%
|
-
|
|
Jul 18
2022
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,704
-0.97%
|
$20,448
$12.87 P/Share
|
|
Jul 18
2022
|
David C Marek Principal Executive Officer |
SELL
Open market or private sale
|
Direct |
11,164
-2.49%
|
$133,968
$12.87 P/Share
|
|
Jul 18
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
1,935
-0.71%
|
$23,220
$12.87 P/Share
|
|
Jul 18
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,606
-0.63%
|
$19,272
$12.87 P/Share
|
|
Jul 06
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
3,702
-1.34%
|
$48,126
$13.4 P/Share
|
|
Jul 06
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,755
-1.06%
|
$35,815
$13.4 P/Share
|
|
May 27
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,382
-0.53%
|
$13,820
$10.07 P/Share
|
|
Apr 19
2022
|
David C Marek Principal Executive Officer |
SELL
Open market or private sale
|
Direct |
24,594
-5.2%
|
$245,940
$10.45 P/Share
|
|
Apr 19
2022
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,049
-3.87%
|
$70,490
$10.45 P/Share
|
|
Apr 19
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,632
-1.75%
|
$46,320
$10.45 P/Share
|
|
Apr 19
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
8,002
-2.82%
|
$80,020
$10.45 P/Share
|
|
Apr 15
2022
|
David C Marek Principal Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,567
+22.16%
|
-
|
|
Apr 15
2022
|
Lauren Merendino Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,703
+36.3%
|
-
|
|
Apr 15
2022
|
Matthew Lang General Counsel & Corp. Secy. |
BUY
Grant, award, or other acquisition
|
Direct |
111,111
+28.12%
|
-
|
|
Apr 15
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,703
+28.14%
|
-
|
|
Apr 15
2022
|
Uneek Mehra Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
111,111
+34.16%
|
-
|
|
Apr 05
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,922
-1.18%
|
$24,986
$13.78 P/Share
|